Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Relationship of age and mood to monoamine metabolites in cerebrospinal fluid in parkinsonism.

× No keyword cloud information.

32 in total

1. Clinical analyses of factors influencing L-dopa treatment of Parkinson's syndrome.

Authors: A K Granerus; G Steg; A Svanborg
Journal: Acta Med Scand Date: 1972 Jul-Aug

2. The probenecid test in Parkinson's disease.

Authors: M B Bowers; M H Van Woert
Journal: Lancet Date: 1972-10-28 Impact factor: 79.321

Review 3. Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain.

Authors: A T Moir; G W Ashcroft; T B Crawford; D Eccleston; H C Guldberg
Journal: Brain Date: 1970 Impact factor: 13.501

4. Psychomotor activity and cerebrospinal fluid amine metabolites in affective illness.

Authors: R M Post; J Kotin; F K Goodwin; E K Gordon
Journal: Am J Psychiatry Date: 1973-01 Impact factor: 18.112

5. 5-Hydroxyindolacetic acid and homovanillic acid in cerebrospinal fluid in manic-depressive psychosis.

Authors: R Sjöström; B E Roos
Journal: Eur J Clin Pharmacol Date: 1972-06 Impact factor: 2.953

6. Abnormalities of indoleamines in affective disorders.

Authors: A Coppen; A J Prange; P C Whybrow; R Noguera
Journal: Arch Gen Psychiatry Date: 1972-05

7. Probenecid test in Parkinson's disease.

Authors: T N Chase; L K Ng
Journal: Lancet Date: 1971-12-04 Impact factor: 79.321

8. Concentrations of 5-hydroxyindolylacetic acid and homovanillic acid in the cerebrospinal fluid of the dog before and during treatment with probenecid.

Authors: H C Guldberg; G W Ashcroft; T B Crawford
Journal: Life Sci Date: 1966-09 Impact factor: 5.037

9. Acid monoamine metabolites of cerebrospinal fluid in mental depression and mania.

Authors: S J Dencker; U Malm; B E Roos; B Werdinius
Journal: J Neurochem Date: 1966-12 Impact factor: 5.372

Review 10. Dopamine (3-hydroxytyramine) and brain function.

Authors: O Hornykiewicz
Journal: Pharmacol Rev Date: 1966-06 Impact factor: 25.468

4 in total

1. Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.

Authors: G Campanella; S Algeri; C Cerletti; E Dolfini; A Jori; F Rinaldi
Journal: Eur J Clin Pharmacol Date: 1977-04-20 Impact factor: 2.953

2. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.

Authors: D L Davidson; C M Yates; C Mawdsley; I A Pullar; H Wilson
Journal: J Neurol Neurosurg Psychiatry Date: 1977-12 Impact factor: 10.154

3. Tryptophan, 5-hydroxyindoleacetic acid and indoleacetic acid in human cerebrospinal fluid: interrelationships and the influence of age, sex, epilepsy and anticonvulsant drugs.

Authors: S N Young; S Gauthier; G M Anderson; W C Purdy
Journal: J Neurol Neurosurg Psychiatry Date: 1980-05 Impact factor: 10.154

Review 4. Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors: Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal: Front Cell Neurosci Date: 2014-11-11 Impact factor: 5.505

4 in total